Role of linezolid in the treatment of orthopedic infections

Bassetti, Matteo; Righi, Elda; Biagio, Antonio Di; Rosso, Raffaella; Beltrame, Andrea; Bassetti, Dante

doi:10.1586/14787210.3.3.343

Cited by 10 publications

(3 citation statements)

References 91 publications

(151 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, its cost and adverse haematological events, such as anaemia and thrombocytopenia, 4,17,19 -29 often limit its use, especially when it is administered for .28 days. Preclinical and Phase I studies 3,7,9,30 have shown that these adverse effects are usually dose dependent and reversible after discontinuation. Nonetheless, some adverse events, namely peripheral neuropathy, optic neuropathy, lactic acidosis and serotonin syndrome, are serious and sometimes irreversible.…”

Section: Introductionmentioning

confidence: 99%

Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia?

Legout

Valette

Dezèque

et al. 2010

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia?

Legout

Valette

Dezèque

et al. 2010

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

show abstract

“…Linezolid is an oxazolidinone, a new class of antibacterial agents particularly effective against Gram-positive infections, including methicillin- and vancomycin-resistant strains [ 38 ]. It is available in oral and intravenous (IV) formulations and has been approved by the Food and Drug Administration for the treatment of numerous infections, including cSSIs or uncomplicated SSIs, without concomitant osteomyelitis, caused by S. aureus [ 39 ].…”

Section: Current Treatment Options For S Aureus Bmentioning

confidence: 99%

Daptomycin in bone and joint infections: a review of the literature

Rice

Mendez-Vigo

2008

Arch Orthop Trauma Surg

View full text Add to dashboard Cite

Introduction To review the pharmacology, pharmacokinetics, efficacy, and safety of daptomycin, a novel antibiotic for the treatment of bone and joint infections, a literature search of relevant articles was conducted. Materials and methods A PubMed/MEDLINE search (1990–April 2008) to identify relevant English-language literature was conducted. Search terms included bone and joint infection, osteomyelitis, daptomycin, and methicillin-resistant Staphylococcus aureus (MRSA). Additional articles were identified by reviewing the bibliographies of articles cited. Programs and abstracts from infectious disease meetings were searched, and prescribing information of antibiotics indicated for bone and joint infections consulted. All articles identified from data sources published in English were evaluated. Results Caused primarily by Gram-positive pathogens such as S. aureus and, to a lesser extent, Enterococcus faecalis, bone and joint infections are difficult to treat successfully. Surgical intervention and prolonged courses of antibiotics are frequently required, and failure of first-line antibiotic therapy is common. The emergence of S. aureus strains with reduced susceptibility to vancomycin, the longstanding gold standard for bone and joint infections, has complicated the clinical scenario. Few randomized trials comparing the efficacy of different antibiotics for bone and joint infections exist. Daptomycin, a novel intravenous lipopeptide antibiotic, has shown potent in vitro activity against a broad spectrum of Gram-positive bacteria, including many resistant pathogens commonly associated with bone and joint infections such as MRSA and vancomycin-resistant E. faecalis. Early clinical investigation of daptomycin in bone and joint infections unresponsive to antibiotics, such as vancomycin, has found a cure rate of approximately 80%, with a low incidence of adverse events and drug resistance. Conclusion Further studies are warranted to determine if limited clinical evidence, described in individual case reports and a daptomycin-specific retrospective registry, suggests daptomycin is a promising option for patients with bone and joint infections such as MRSA osteomyelitis.

show abstract

“…In 2000, linezolid was the first oxazolidinone antibiotic approved by the US Food and Drug Administration (FDA) for clinical use [ 15 , 16 , 17 ]. This oxazolidinone antibiotic has been used for the treatment of patients with skin and soft tissue infection and pneumonia caused by MDR Gram-positive pathogens [ 18 , 19 , 20 , 21 ]. However, it has been reported that several linezolid-resistant staphylococci have emerged worldwide [ 22 , 23 , 24 ].…”

Section: Introductionmentioning

confidence: 99%

In Vitro Activities of LCB 01-0648, a Novel Oxazolidinone, against Gram-Positive Bacteria

Kim

Baek³

et al. 2017

Molecules

View full text Add to dashboard Cite

Oxazolidinones are a novel class of synthetic antibacterial agents that inhibit bacterial protein synthesis. Here, we synthesized and tested a series of oxazolidinone compounds containing cyclic amidrazone. Among these compounds, we further investigated the antibacterial activities of LCB01-0648 against drug-susceptible or resistant Gram-positive cocci in comparison with those of six reference compounds. LCB01-0648 showed the most potent antimicrobial activities against clinically isolated Gram-positive bacteria. Against the methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant coagulase-negative staphylococci (MRCNS) isolates, LCB01-0648 showed the lowest MIC90s (0.5 mg/L) among the tested compounds. In addition, LCB01-0648 had the lowest minimum inhibitory concentrations (MICs) against the four linezolid-resistant S. aureus (LRSA) strains (range 2–4 mg/L). The results of the time–kill studies demonstrated that LCB01-0648 at a concentration 8× the (MIC) showed bactericidal activity against methicillin-susceptible Staphylococcus aureus MSSA or MRSA, but showed a bacteriostatic effect against LRSA. These results indicate that LCB01-0648 could be a good antibacterial candidate against multidrug-resistant (MDR) Gram-positive cocci.

show abstract

Role of linezolid in the treatment of orthopedic infections

Cited by 10 publications

References 91 publications

Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia?

Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia?

Daptomycin in bone and joint infections: a review of the literature

In Vitro Activities of LCB 01-0648, a Novel Oxazolidinone, against Gram-Positive Bacteria

Contact Info

Product

Resources

About